Thymosin Alpha-1
A peptide responsible for restoring and modulating immune function, used in infections and chronic illness.
Common Dosage
1.6mg 2x weekly
Category
Immunity
- Immune modulation
- Viral defense
- Cancer support adjunct
Thymosin Alpha-1 (Ta1) is a 28-amino-acid peptide naturally produced by the thymus gland, where it plays a role in T-cell maturation and immune regulation. It was first isolated by Allan Goldstein and colleagues at George Washington University in the 1970s during research on thymus-derived immune factors. The synthetic form (Thymalfasin, marketed as Zadaxin by SciClone Pharmaceuticals) has been approved in over 35 countries for hepatitis B, hepatitis C (as interferon adjunct), and as a vaccine adjuvant. It holds a unique position among research peptides as one of the few with extensive clinical validation.
Thymosin Alpha-1 stimulates T-lymphocyte maturation, particularly Th1 cells responsible for cell-mediated immunity against intracellular pathogens and cancer cells. It upregulates MHC class I and II expression on antigen-presenting cells, enhancing immune recognition of viral and tumor antigens. It also modulates dendritic cell function and reduces T-regulatory cell activity that tumors use to evade immune detection — making it relevant for both infection defense and cancer immunotherapy adjunct use.
- Chronic hepatitis B treatment — approved in multiple countries
- Hepatitis C treatment adjunct with interferon
- Immunocompromised states including HIV, cancer chemotherapy
- Vaccine adjuvant to enhance immunogenicity
- Sepsis immune modulation
- Cancer immunotherapy adjunct
- COVID-19 treatment protocols (studied extensively in China)
Hepatitis B Clinical Outcomes
Multiple randomized controlled trials and meta-analyses have documented significant improvements in hepatitis B e-antigen seroconversion rates and HBV DNA suppression with Thymalfasin treatment, particularly when combined with antiviral therapy — supporting its regulatory approval for this indication.
COVID-19 Outcomes
Retrospective Chinese studies and early clinical trials in COVID-19 patients treated with Thymosin Alpha-1 showed reduced mortality in severe cases, attributed to its ability to restore the Th1-mediated antiviral response which is often suppressed in severe COVID. These results generated significant international interest.
Cancer Adjunct Therapy
Use of Thymosin Alpha-1 alongside conventional chemotherapy in lung and liver cancer patients has shown improvements in immune cell counts, quality of life, and in some studies, improved overall response rates — consistent with immune restoration during chemotherapy-induced immunosuppression.
- Generally very well tolerated — among the best safety profiles of any peptide therapy
- Autoimmune conditions warrant caution — enhanced T-cell activation could exacerbate autoimmune flares
- Cost of pharmaceutical-grade Thymalfasin is significant; research-grade alternatives have variable quality
- Overactivation of immune response is theoretically possible in certain settings
- Not approved in the US specifically — this limits access to pharmaceutical-grade product for domestic users
- Generally well tolerated